TAS-103 is a dual DNA topoisomerase I/II (topoisomerase I/II) inhibitor for cancer research.
in vivo
TAS-103 (30 mg/kg, iv) causes significant tumor growth suppression in mice bearing Lewis lung carcinoma (LLC) cells, without obvious body weight loss, and the liposomal TAS-103 is more active than free TAS-103.
